Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

86%

6 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4

5(71.4%)

N/A

1(14.3%)

Phase 3

1(14.3%)

7Total

Phase 4(5)

N/A(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT01847105Not ApplicableUnknown

Assessing Patient Comfort With Two Different Multi-Purpose Disinfecting Solutions

Role: lead

NCT01390961Phase 4Unknown

Comparison of Tolerability Between Two Allergy Drops

Role: lead

NCT01337557Phase 4Unknown

Use of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% for Allergic Conjunctivitis and Contact Lenses

Role: lead

NCT01335126Phase 3Unknown

Comparison of Tolerability and Clinical Performance of Two Emulsion-type Artificial Tears

Role: lead

NCT01227226Phase 4Unknown

Tear Osmolarity Over Time With Artificial Tears

Role: lead

NCT00489398Phase 4Withdrawn

Comparison of CL Wear Between Two Allergy Drops

Role: lead

NCT00817557Phase 4Unknown

Use of Loteprednol for Contact Lens Intolerance and Dryness

Role: lead

All 7 trials loaded